Glaucoma is the second-leading cause of acquired blindness, and the ques on of how to appropriately diagnose, treat, and manage the disease is of vital importance not only in maintaining pa ents' quality of life, but also in stemming the increasing burden on society imposed by the disease. With recent technological innova ons, increasing a en on has been focused on maintaining and increasing therapeu c standards, and there has been an increasingly pressing need in recent years for glaucoma treatment guidelines in order to improve the quality of therapy. In addi on, it is necessary to reduce health care expenses by efficiently u lizing resources from the standpoint of globaliza on of health care and medical economics. Nigeria Standard Treatment Guidelines (STG), have no recommenda on for the treatment and management of glaucoma.
Objec ves
To design a treatment guideline for primary open angle (POAG) that is more cost effec ve from the perspec ve of a third party payer than the current prac ce based on real world evidence.
Methods
A retrospec ve descrip ve study of glaucoma pa ents was carried out with the aid of a data collec on form. The prices (95% CI) of an glaucoma drugs were es mated from hospital price list and the 5 nearby community pharmacies. Eighty randomly selected case notes of glaucoma pa ents who had been on therapy for at least 3 months was studied. Data collected were the demographics, diagnosis, intra ocular pressure (IOP) per month and the drugs prescribed. A Stochas c Monte Carlo model based on the outcome and cost was constructed with the aid of vanguard studio 5.0 (Cary, North Carolina, USA). The input data were 95% CI of the prices of prescribed an glaucoma drugs and the outcome of the therapy which was entered as the propor on of pa ents whose IOPs were normal, reduced or either increased or unchanged per month of treatment. The drugs prices were entered as a uniform distribu on while the outcome values were fixed. Sensi vity analysis was conducted by varying the input data by ±50%. (Figure 2 ) 
Conclusion
The pa ents that IOP was checked regularly were low and mul therapy was prescribed at onset with the Beta blockers plus Carbonic anhydrase inhibitors. A cost savings of NGN69, 830.64 ($440.71) will be obtained by the proposed guideline for POAG per pa ent per annum thus it could be adopted a er evalua on at several sites. 
Cost-Effec veness
A high percentage of pa ents were on mul drug therapy at onset instead of op mizing different monotherapy to reduce side effects. In the study by Omo et al. (2010) the lowest annual cost of medical therapy was associated with monotherapy ( molol maleate 0.5% drops), while the highest annual cost of medical therapy was related to combina on therapy and prostaglandin analogues such as latanoprost 0.005% (Xalatan®) or travoprost (Travatan®). Cost-effec veness should be considered along with tradi onal clinical safety and efficacy measures to make individual and group healthcare decisions as opined by Noecker et al. (2006) . The result of this study clearly showed that the amount of money currently spent per pa ent in the management of POAG in the study site per month could be used to manage three pa ents in nine months with an improved outcome. In this guideline, the pa ents were started on betablockers (BB), for pa entsthat were stable or improved, they con nued on the same therapy. While those that failed, carbonic anhydrase inhibitors were added (BBCAI), pa ents with par ally improved status then had prostaglandins analogues added to their therapy which produced posi ve outcome. The propor on of pa ents whose IOP was checked regularly was low (26.76%). Also many of the glaucoma pa ents 55 (68.75%) had different combina on drugs at onset and a er one month of therapy; despite that they experienced therapeu c failure and their IOP did not reduce to normal (bellow 21 mmHg). The commonest drugs prescribed were the beta blockers and combina on of beta blockers and carbonic anhydrase inhibitors as seen in Table 1 . The current prac ce will cost NGN 77,783.76 ($490.90) per pa ent per annum (figure 1) whereas the proposed guideline that resulted in an improved outcome will cost NGN7,953.12 ( $50.19) (figure 2) At the me of this report $1USD was equivalent to 158.45NGN (Nigerian naira).
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